Xenetic Biosciences, Inc. (NASDAQ:XBIO) Shares Shorted: Short Interest Down 42.7% in September
by Kim Johansen · The Markets DailyXenetic Biosciences, Inc. (NASDAQ:XBIO – Get Free Report) saw a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 12,868 shares, a decline of 42.7% from the September 15th total of 22,465 shares. Based on an average trading volume of 277,145 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.6% of the shares of the company are short sold.
Xenetic Biosciences Price Performance
Shares of Xenetic Biosciences stock opened at $2.11 on Thursday. The firm has a fifty day moving average price of $3.18 and a 200 day moving average price of $3.05. Xenetic Biosciences has a 1 year low of $1.87 and a 1 year high of $5.28. The stock has a market cap of $4.83 million, a PE ratio of -1.82 and a beta of 2.19.
Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter. Xenetic Biosciences had a negative net margin of 75.90% and a negative return on equity of 40.62%. The business had revenue of $0.66 million for the quarter.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company has an average rating of “Sell”.
Get Our Latest Stock Report on XBIO
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for oncology. The company’s research is centered on treatments for difficult-to-treat cancers, including hematologic malignancies.
Xenetic’s principal technology is XCART, a personalized chimeric antigen receptor T-cell therapy platform designed to create individualized treatments that target tumor-specific antigens on a patient’s cancer cells. The platform has been developed with an initial focus on B-cell malignancies, including multiple myeloma, where tumor heterogeneity can limit the effectiveness of conventional therapies.
The company’s activities primarily involve research, preclinical development and clinical advancement of its oncology pipeline through collaborations and strategic partnerships.